Skip to Main Content

Biogen, a stalwart of the global drug industry for the past four decades, is perilously poised for 2022.

The company’s Tuesday decisions to replace CEO Michel Vounatsos and cut nearly all spending marketing the Alzheimer’s disease treatment Aduhelm resolved some of the questions swirling around the embattled biotech.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment